Complete Guide to Growth Hormone Research Peptides UK

Growth hormone research peptides operate through several distinct mechanisms that are important to understand when designing research protocols. GHRH analogues, ghrelin mimetics and IGF-1 analogues each target different points in the GH/IGF-1 axis.

GHRH Analogues: Sermorelin (GRF 1-29) and CJC-1295 are synthetic analogues of growth hormone releasing hormone. They stimulate the anterior pituitary to release GH via the GHRH receptor. CJC-1295 without DAC (Modified GRF 1-29) has a short half-life of approximately 30 minutes, producing physiological GH pulses. CJC-1295 with DAC extends this to approximately 8 days via albumin binding, producing sustained GH elevation.

Ghrelin Mimetics and GHRP Compounds: Ipamorelin, GHRP-2, GHRP-6 and Hexarelin activate the GHSR-1a (ghrelin receptor) to stimulate GH release. Ipamorelin is the most selective — research demonstrates minimal effects on cortisol, prolactin or ACTH. GHRP-2 shows strong GH release with moderate cortisol effects. GHRP-6 research examines appetite stimulation via ghrelin receptor activation alongside GH release. Hexarelin is among the most potent synthetic GH secretagogues studied, with additional cardiovascular research applications.

Oral GH Secretagogue: MK-677 (Ibutamoren) is a non-peptide, orally active ghrelin mimetic that sustains GH and IGF-1 elevation over 24-hour periods, making it unique among GH research compounds.

IGF-1 Analogues: IGF-1 LR3 acts systemically with extended half-life via reduced binding protein affinity. IGF-1 DES acts locally with higher receptor potency. IGF-2 and Mechano Growth Factor examine specific aspects of the IGF signalling system in research models.

All GH research peptides from UK Peptides are supplied at 99%+ HPLC purity for research purposes only.

⚠️ Research Disclaimer: This guide is for informational and scientific research context only. All UK Peptides compounds are sold strictly for laboratory research. Not for human consumption.